Development and validation of a prediction model for microvascular invasion in hepatocellular carcinoma

Table 2 Univariate logistic regression analysis of preoperative data for microvascular invasion presence in the training cohort

Variable	OR (95%CI)	P value
Age, yr	0.981 (0.962–1.001)	0.062
Gender, male vs female	1.488 (0.823–2.689)	0.188
Number of tumors, multiple vs single	5.174 (2.611–10.252)	< 0.001
Tumor size, cm	1.214 (1.155–1.332)	< 0.001
Etiology, non-hepatitis B vs hepatitis	0.837 (0.511–1.370)	0.479
AFP, ng/mL
20–40 vs ≤ 20	1.936 (1.100–3.407)	0.022
≥ 400 vs ≤ 20	4.546 (2.687–7.691)	< 0.001
WBC, 109/L, > 4.0 vs ≤ 4.0	1.117 (0.711–1.927)	0.537
Neutrophils, 109/L, >3.0 vs ≤ 3.0	1.989 (1.289–3.069)	0.002
PLT, 109/L, > 125 vs ≤ 125	1.375 (0.883–2.143)	0.159
RDW, > 13.0 vs ≤ 13.0	1.116 (0.713–1.748)	0.630
NLR, > 2.0 vs ≤ 2.0	1.927 (1.244–2.983)	0.003
PLR, > 100 vs ≤ 100	1.945 (1.261–3.000)	0.003
SII, > 300 vs ≤ 300	2.170 (1.404–3.352)	< 0.001
PT, sec, > 13 vs ≤ 13	1.514 (0.931–2.462)	0.094
ALB, g/L, > 40 vs ≤ 40	0.949 (0.617–1.460)	0.812
ALT, U/L, > 40 vs ≤ 40	0.882 (0.570–1.366)	0.575
AST, U/L, > 35 vs ≤ 35	1.275 (0.831–1.958)	0.266
GGT, U/L, > 45 vs ≤ 45	1.486 (0.947–2.334)	0.085
TB, μmol/L, > 19 vs ≤ 19	1.297 (0.788–2.133)	0.307
ALP, U/L, > 120 vs ≤ 120	1.677 (1.078–2.610)	0.022
FIB, g/L, > 2.0 vs ≤ 2.0	1.397 (0.852–2.290)	0.185
GLU, mmol/L, > 6.1 vs ≤ 6.1	0.904 (0.518–1.579)	0.723
ALBI grade, 1 vs 2 and 3	1.266 (0.825–1.942)	0.281

AFP: α-fetoprotein; WBC: White blood cells; PLT: Platelets; RDW: Red blood cell distribution width; NLR: Neutrophil–lymphocyte ratio; PLR: Platelet–lymphocyte ratio; SII: Systemic immune-inflammation index; PT: Prothrombin time; FIB: Fibrinogen; ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate transaminase; GGT: γ-glutamyltransferase; TB: Total bilirubin; ALP: Alkaline phosphatase; GLU: Glucose; ALBI: Albumin-bilirubin; OR: Odds ratio; CI: Confidence interval.